Abstract: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig ’s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord. This leads to muscle weakness, paralysis, and ultimately, respiratory failure (Cha and Kim, 2022). There is currently no cure for ALS. Riluzole, a primary treatment for ALS, has been shown to extend survival by an average of three months. Another drug, Edaravone, has been approved for ALS treatment in some countries; however, its efficacy remains controversial (Cha and Kim, 2022). These drugs target various mechanisms that contribute to neuronal degeneration in ALS, including glutamate excitotoxicity and oxidative stress. Although several studies have attempted to elucidate the underlying mechanisms, there remains an unmet need for more effective therapies to halt or reverse disease progression. Therefore, novel therapeutic strategies are urgently needed.